-- Days : -- HRS : -- MIN : -- SEC

Register Now →

Subscribe

News
Video
Podcasts
Journals
Conferences
Events
Resources
CE
About AJMC
Subscribe

Spotlight -

Free In-Person Regional Events Focused on Oncology and Population Health

Opinion|Videos|August 28, 2024

Examining Trial Data on Omaveloxolone Efficacy

A physician examines clinical trial results that impact their approach to treating patients with Friedreich ataxia.

Episodes in this series

This series features 1 kol.

EP. 1 Friedreich Ataxia: Addressing Treatment Objectives and Comorbidities

This series features 1 kol.

EP. 2 Guidelines & FDA Approval of Novel Friedreich Ataxia Therapy

This series features 1 kol.

EP. 3 Engaging mFARS Scale to Monitor Friedreich Ataxia Progression

This series features 1 kol.

EP. 4 Managing Adverse Events in Novel Friedreich’s Ataxia Therapy

This series features 1 kol.

EP. 5 Examining Trial Data on Omaveloxolone Efficacy

This series features 1 kol.

EP. 6 Promising Therapy Approaches for Advanced Friedreich Ataxia

Susan Perlman, MD, an expert on Friedreich's ataxia

EP. 7 Friedreich Ataxia: Looking Forward at the Treatment Landscape

Susan Perlman, MD, an expert on Friedreich's ataxia

EP. 8 Epidemiology, Pathophysiology, and Symptomatology of Friedreich Ataxia

Susan Perlman, MD, an expert on Friedreich's ataxia

EP. 9 Diagnosis of Friedreich Ataxia

Susan Perlman, MD, an expert on Friedreich's ataxia

EP. 10 Impact of Friedreich Ataxia on Quality of Life

Susan Perlman, MD, an expert on Friedreich's ataxia

EP. 11 Clinical Utility of the Modified Friedreich Ataxia Rating Scale

Susan Perlman, MD, an expert on Friedreich's ataxia

EP. 12 Comorbidities and Complications Associated With Friedreich Ataxia

Susan Perlman, MD, an expert on Friedreich's ataxia

EP. 13 Challenges Associated With Friedreich Ataxia

Susan Perlman, MD, an expert on Friedreich's ataxia

EP. 14 Future Considerations for Friedreich Ataxia

In 2023, a propensity matched comparison of MOXIe extension patients to an untreated cohort found a significant slowing of disease progression per mFARS of 3.0 points compared to 6.6 points, respectively. Are these results clinically meaningful for patients and how does this relate to your everyday clinical practice?

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Content

Mixed Phase 3 Results for IB6-Targeting ADC Raise Questions on Optimal Use in NSCLC

ByBrooke McCormick

June 23rd 2026

Joseph K. Han, MD

How Upstream Biologics Could Transform CRSwNP Care: Joseph K. Han, MD

BySabrina McCrear,Joseph K. Han, MD

June 23rd 2026

X-ray scan with patient. | Image Credit: DraganaGordic_AdobeStock.jpeg

Familial Pulmonary Fibrosis Linked to Faster Lung Function Decline, UIP Pattern

BySabrina McCrear

June 23rd 2026

Ocrelizumab | Image credit: Semi - stock.adobe.com

Switch to Ocrelizumab Shows Safety in Patients With Relapsing MS

ByJulia Bonavitacola

June 23rd 2026

Experts featured in this series.

The Right Fit First: How Psychiatrists Approach Initial Treatment and Patient Adherence

ByPatrick Runnels, MD, MBA,Ginger Shupe, MD,Gus Alva, MD, DFAPA,Joe Goldberg, MD

Published: June 23rd 2026 | Updated: June 16th 2026

Trending on AJMC

Legend Biotech’s CAR T-cell Therapy Shows Early Promise in SCLC, Other Tumors

Flatiron’s AI-Driven Telescope Makes Data Access More User-Friendly

Social Factors May Match, Outpace Genetic Risk in Disease Prediction

Long-Term, Consistent Resistance Training Linked to Substantially Lower Type 2 Diabetes Risk

SLEEP 2026 Annual Meeting Highlights Past and Future of Sleep Medicine